Compare · FLXN vs TCDA
FLXN vs TCDA
Side-by-side comparison of Flexion Therapeutics, Inc. (FLXN) and Tricida Inc. (TCDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. FLXN focuses on Major Pharmaceuticals, while TCDA focuses on Biotechnology: Pharmaceutical Preparations.
- TCDA is the larger of the two at $550.1M, about 1.2x FLXN ($458.9M).
- FLXN has more recent analyst coverage (7 ratings vs 2 for TCDA).
- Company
- Flexion Therapeutics, Inc.
- Tricida Inc.
- Price
- $25.11-0.20%
- $0.10-19.25%
- Market cap
- $458.9M
- $550.1M
- 1M return
- -0.20%
- -
- 1Y return
- -1.57%
- -
- Industry
- Major Pharmaceuticals
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2018
- News (4w)
- 0
- 0
- Recent ratings
- 7
- 2
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Tricida Inc.
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)
Latest TCDA
- SEC Form EFFECT filed by Tricida Inc.
- SEC Form 15-12G filed by Tricida Inc.
- SEC Form S-8 POS filed by Tricida Inc.
- SEC Form POSASR filed by Tricida Inc.
- SEC Form POS AM filed by Tricida Inc.
- Tricida Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tricida Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits